PIMG
BBIO icon

Patriot Investment Management Group’s BridgeBio Pharma BBIO Stock Holding History

Patriot Investment Management Group’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-530
Closed -$17.3K – 238
2020
Q2 		$17.3K Buy
+530
New +$16.1K ﹤0.01% 443

Other funds holding BBIO

KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIG
American International Group New York $609M AUM 23.67% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
SUT
SC US (TTGP) Menlo Park, California $9.25B AUM 20.49% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Patriot Investment Management Group's BBIO Position: Q3 2020 in Review

Patriot Investment Management Group sold out of BridgeBio Pharma (BBIO) in Q3 2020, closing a stake of 530 shares — an estimated $17.3K sold.

Patriot Investment Management Group first reported a position in BBIO in Q2 2020 and held it in 1 quarter. The position peaked at $17.3K in Q2 2020. 129 funds tracked by Wall St. Rank hold BBIO as of Q3 2020.

  • Patriot Investment Management Group reported no remaining BridgeBio Pharma position as of Q3 2020 after selling out during the quarter.
  • Patriot Investment Management Group sold 530 BridgeBio Pharma shares in Q3 2020, an estimated $17.3K.
  • Patriot Investment Management Group first reported a position in BridgeBio Pharma in Q2 2020 and held it in 1 quarter.
  • Patriot Investment Management Group's BridgeBio Pharma position peaked at $17.3K in Q2 2020.
  • 129 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q3 2020.

Based on Patriot Investment Management Group's 13F filing for Q3 2020, filed 23 Oct 2020.